PDB36 Diet modification in patients with diabetes and its association with heath care utilization and expenditure  by Alfaifi, A. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A243
patients. ConClusions: This BIA will be essential to support CONITEC’s decision 
about insulin analogues for T1DM patients in Brazil. Treatment costs still impressive, 
considering that analogues’ values reach 10 times the unit values of human insulins, 
fact that did not happen in other countries where they are already covered.
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The alBigluTiDe BuDgeT imPacT moDel iPaD aPPlicaTion – a new, 
inTeracTive, user-frienDly PlaTform DemonsTraTing The BuDgeT 
imPacT of incluDing alBigluTiDe on manageD care formularies
Bruhn D.1, Roberts G.2, Spain C.V.3, O’Leary M2
1GSK, RTP, NC, USA, 2Double Helix, London, UK, 3GSK, Philadelphia, PA, USA
objeCtives: The budget impact model (BIM) is recognized as a useful tool to help 
payers assess the economic value of new medicines approved for use. Although 
they are not considered as robust as cost effectiveness models, they do allow for 
short-term estimates of pharmacy impact and potential costs/offsets with the 
inclusion of the new medicine on formulary. Evolving IT platforms, such as the 
iPad, are offering new opportunities, but also changing end user expectations for 
these models. Albiglutide is an investigational, once weekly, Glucagon-Like Peptide-1 
Receptor Agonist (GLP-1RA) for the treatment of Type 2 Diabetes (T2D). We describe 
the development of an iPad application (app) derived from an excel-based BIM 
for use with US payer customers to inform access and reimbursement decisions 
for albiglutide. Methods: An excel-based BIM estimating the 1-5 year impact 
of including albiglutide on formulary compared to other available GLP-1RA’s was 
developed as per guidance from AMCP and following ISPOR good research prac-
tices. Given the increased use and demand for apps, we transformed the excel 
model into an app that would allow for modeling simulations to be run on an iPad 
adhering to these good practice guidelines. Results: The excel model was built 
according to the good practice guidelines and demonstrated the budget impact of 
introducing albiglutide for the treatment of T2D. The BIM was designed in a way 
to allow for successful conversion into a standalone app that utilized an improved 
user interface for interactive discussions around the value of albiglutide with US 
payers. ConClusions: The app version of the albiglutide BIM is a useful, comple-
mentary tool to the excel-based BIM. The app maintains its functionality according 
to ISPOR and AMCP recommendations.
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somaTroPin Dose analysis for TreaTmenT of hyPoPiTuiTarism in 
PuBlic Brazilian healTh sysTem (sus)
Ferreira C.N., Rufino C.S., Manfrin D.F.
Pfizer, Inc., São Paulo, Brazil
objeCtives: This analysis aims to determine, in International Units (IU), the soma-
tropin volume waste of presentations with 4 IU and 12 IU compared to 16 IU and 
36 IU, when used for treatment of Turner Syndrome and for children treatment 
with disorders of growth due to deficiencies of growth hormone. Methods: The 
amount waste per month was analyzed, in IU, from the dosage indicated in the 
Project of Clinical Protocol Guideline (PCDT) for Hypopituitarism of the Brazilian 
Health Ministry and a comparative analysis was done between presentations of 
4 IU/ 12 IU (approved by Ministry) and of 16 IU/ 36 IU. Results: The average loss 
per treatment/month (Turner Syndrome and children with growth disorders) are 
18,36 IU, 12,08 IU, 0,38 IU and 2,01 IU presentations with 4IU,12IU, 16IU and 36IU 
respectively. ConClusions: Therefore, if the SUS adopt presentations of 16IU or 
36IU, that could be reduce the losses in an average of 97,5% and 87% respectively in 
month/patient, minimize the treatment cost, optimize doses number and achieve 
more patients. Moreover, it is more advantageous because they take up less space 
for storage and for transportation.
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imPacT of DiaBeTes in family healTh sPenDing in Brazilian 
PoPulaTion
Zaccolo A.1, Carraro W.H.1, Rosa R.D.S.1, Duncan B.B.1, Prince D.2
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objeCtives: To estimate the impact of the cost of diabetes mellitus (DM) in 
Brazil based on the ratio (“R”) of health care expenses of households with at least 
one person using medication for diabetes to those without diabetes medication 
use. Methods: We utilized data from the Family Budget Study (POF – Pesquisa de 
Orçamentos Familiares), a representative sample of 59.548 households investigated 
in 2008-2009 by the Brazilian Institute of Geography and Statistics (IBGE). The data 
were analyzed using Microsoft Excel and R (version 3.0.2). Households were catego-
rized based on the purchase (or no cost receipt) of diabetes medications by fam-
ily members. Expenses included those for hospitalization, medical consultations, 
health insurance, drugs and medical supplies. Analyses were conducted for Brazil, 
for regions and for those with and without health insurance coverage. Results are 
weighted so as to represent the Brazilian population. Results: Households with 
diabetes (6.2% of the total) more frequently (26.3% vs. 8.5%) had members > 60 years 
of age. Expenses increased with increasing household income. Overall, for Brazil, 
the ratio “R”, adjusted through regression analyses for the age and sex distribution 
of the family members, household income and regional location, was 1.81 (95%CI 
1.69-1.95), indicating that expenses were 81% greater in households where diabetes 
was present than in those without. The expenses with the purchase of medicines to 
treat DM increase with increasing income. ConClusions: Health care expenses 
are notably greater in Brazilian households having family members with diabetes.
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(T2Dm) TreaTmenT in venezuela: a BuDgeT imPacT analysis
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objeCtives: To estimate the budget impact of the use of saxagliptin/metformin 
XR fixed-dose combination compared to the current treatment of people with 
T2DM, in Venezuela. Methods: We used an MS Excel-based budget impact model 
assuming coverage of one million people in the health care system of Venezuela, 
with a 3-year time horizon. DM prevalence was obtained from published literature. 
Pharmaceutical expenses of oral antidiabetic agents (OADs) were analyzed exclud-
ing other medical costs. The cost of OADs was based upon list prices, expressed 
in Venezuelan Bolivars (VEF$) 2013 (exchange rate: 1 US-dollar = 6.30 VEF$). The 
market share of the different drugs was based upon QUALIDIAB Database, market 
studies and data provided by Bristol-Myers Squibb. A progressive increase of mar-
ket share was assumed for saxagliptin/metformin XR among all the OADs; 1.14%, 
2.65% and 3.0% for the 1st, 2nd and 3rd year, respectively. The budget impact is 
reported in terms of annual budget impact, per member per-month (PMPM) and 
per patient per month (PPPM). A Monte Carlo simulation (10,000 iterations) was 
done as part of the sensitivity analysis. Results: the net budget impact estimated 
for the introduction of saxagliptin/metformin XR combined was VEF$503,807 for 
the first year, VEF$1,183,333 for the second year and VEF$1,353,554 for the third 
year; the cumulative net budget impact was VEF$3,040,703. PMPM was VEF$0.04, 
VEF$0.10 and VEF$0.11 for the first, second and third year respectively. PPPM was 
VEF$1.67, VEF$4.0 and VEF$4.65 each year, respectively. The cumulative impact in 
the total annual budget for oral antidiabetic agents represented an increase of 2.36%. 
Monte Carlo simulation showed that cumulative budget impact varied from 1.32 to 
8.74%. ConClusions: incorporation of saxagliptin/metformin XR combination into 
the health care system of Venezuela, as a treatment option for people with T2DM, 
would have a minimal budgetary impact.
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BuDgeT imPacT analysis of uTilizing canagliflozin (cana) for The 
TreaTmenT of TyPe 2 DiaBeTes melliTus (T2Dm) in an uniTeD sTaTes 
healTh Plan
Vo L., Martin S.
Janssen Scientific Affairs, LLC, Raritan, NJ, USA
objeCtives: CANA, an SGLT2 inhibitor, is a recently approved oral antihyperglyce-
mic agent (AHA) for the treatment of adults with T2DM. As the prevalence and cost 
of T2DM continue to rise, payers seek treatment options to improve care and reduce 
cost. Budget impact analysis may help payers in the formulary decision-making 
process. To estimate the three-year budget impact of adding CANA to a hypothetical 
health plan formulary in place of other branded AHAs. Methods: The model was 
developed from the perspective of a US health plan with 1 million members. The 
prevalence of people diagnosed and treated with T2DM is based on US epidemiol-
ogy statistics. Drug costs were estimated using August 2013 wholesale acquisition 
costs. Publically available estimates of 2012 market shares of the branded AHAs and 
estimated 2013, 2014, and 2015 market shares of CANA for Years 1-3 (Year 1: 0.3%, 
Year 2: 1.8%, Year 3: 2.1%) were used. The base case analysis examined an increasing 
CANA market share with a proportional decrease in the market share of the other 
branded drugs. Results are presented as the difference in pharmacy budget, overall 
and per-member per-month (PMPM). Results: Prior to the introduction of CANA, 
the estimated pharmacy budget for branded non-insulin AHAs in this hypothetical 
plan was almost $48 MM/year. With CANA added to the formulary, the budget is 
forecasted to decrease by $71,902 at Year 1, $431,409 at Year 2, and $503,311 at Year 
3. The PMPM expenditures decrease from $4.00 when CANA was unavailable to $3.95 
at Year 3 of CANA uptake. ConClusions: The results show the positive budget 
impact of adding CANA to the formulary. As payers continually face rising health 
care costs, an AHA that can safely and effectively treat T2DM and lower pharmacy 
costs would be considered highly valuable.
PDB32
BuDgeT imPacT analysis of insulin analogues for TyPe 1 DiaBeTes: 
The case of The Brazilian PuBlic healTh sysTem (sus)
Laranjeira F., Mega T.P., Lima L.P.S., Salomon F.C.R., Petramale C.
Brazilian Ministry of Health, Brasília-DF, Brazil
objeCtives: Type 1 Diabetes Mellitus (T1DM) is an endocrine autoimmune disease 
with onset usually in childhood and which, being chronic, affects people of working 
age. It affects approximately 0.3% of the population and has high personal and social 
impact. The National Committee for Incorporation of Technologies in Health System 
(CONITEC) is responsible for recommending the inclusion or not of technologies in 
Brazilian public health system and has drawn up a budget impact analysis (BIA) of 
insulin analogues for the treatment of T1DM for help the decision making. Methods: 
A BIA of insulin analogues in SUS compared to human insulin (NPH and Regular) 
was performed. The analysis’ time horizon was 5 years, using a diabetes prevalence 
of 7.6% and 5% of T1DM between them (602,742), considering an annual growth rate 
of 0.8143% and a market share of 20%, 30%, 40%, 50% and 100%. The mean total 
insulin dose considered was 0.75IU/kg/day, with an average personal weight of 70kg, 
which means 52.5IU/day, 50% of each insulin type (basal and rapid). Unit purchase 
prices of insulins were obtained in the health system prices database and calcu-
lated the weighted average. For human insulins, were considered the values of last 
purchase of the Ministry of Health. Results: The budget impact of basal analogues 
would be R$202.8 million in the 1st year, considering 20% of target population, reach-
ing approximately R$1 billion in 100% of patients. For rapid analogues, the budget 
impact would be R$62.9 million in the 1st year, reaching R$324.9 million in 100% of 
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PPPM), the propensity score method was less robust against unobserved confound-
ing factors than the doubly robust estimation method.
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healTh care cosTs among TyPe 2 DiaBeTes melliTus PaTienTs 
iniTiaTing glucagon-like PePTiDe-1 recePTor agonisT (glP-1ra) 
TheraPy
Johnston S.S.1, Nguyen H.2, Felber E.2, Cappell K.1, Nelson J.1, Chu B.C.3, Kalsekar I.2
1Truven Health Analytics, Bethesda, MD, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 
3Truven Health Analytics, Santa Barbara, CA, USA
objeCtives: To compare health care costs between type 2 diabetes mellitus 
(T2DM) patients newly initiating exenatide once weekly (exenatide QW), exena-
tide twice daily (exenatide), or liraglutide (LIRA). Methods: This administra-
tive claims-based retrospective cohort study included patients if they had T2DM, 
were GLP-1RA-naïve, initiated a GLP-1RA between 2/1/2012-6/30/2012 (initiation 
date= index), were aged ≥ 18 years, and had continuous enrollment for 12 months 
before (baseline) to 6 months after index (follow-up). Outcomes included health 
care costs (Total/Diabetes-related/GLP-1RAs) and hospitalizations (Total/Diabetes-
related). Diabetes-related outcomes included those associated with antidiabetes 
medications and medical claims coded with T2DM ICD-9-CM codes. Outcomes were 
compared between index GLP-1RAs using multivariable generalized linear models. 
Pre-specified sensitivity analyses were performed stratifying by LIRA 1.2mg and 
LIRA 1.8mg and among patients with ≥ 60 days’ supply of their index GLP-1RA within 
≤ 67 days after index (initial adherers). Results: The study sample included 1,610 
exenatide QW, 2,690 exenatide, and 6,499 LIRA patients. In multivariable-adjusted 
models, health care costs varied widely across GLP-1RAs and analyses, with exena-
tide generally being associated with the lowest adjusted health care costs (cost 
ratios vs. exenatide QW ranging from 0.762 [p< 0.001] for GLP-1RA costs to 0.908 
[p< 0.001] for Total costs among initial adherers). LIRA 1.8mg was generally associ-
ated with the highest adjusted health care costs (cost ratios vs. exenatide QW rang-
ing from 1.039 [p= 0.080] for Total costs to 1.157 [p< 0.001] for GLP-1RA costs among 
initial adherers). LIRA 1.2mg was generally associated with the highest adjusted 
odds of hospitalizations (odds ratios vs. exenatide QW ranging from 1.312 [p= 0.317] 
for diabetes-related hospitalizations to 1.528 [p< 0.036] for total hospitalizations 
among initial adherers). ConClusions: Among patients newly initiating exenatide 
QW, exenatide, or LIRA, differences existed in health care costs and hospitalization 
in first 6 months of treatment. LIRA 1.8mg and 1.2mg were generally associated 
with the highest adjusted health care costs and odds of hospitalization, respectively.
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comParaTive cosT analysis for TreaTing growTh hormone 
Deficience in Brazil: Pen versus syringes
Silva M.A.1, Mello I.M.1, Fernandes R.A.1, Almeida B.G.B.1, Manfrin D.F.2, Ferreira C.N.2
1ANOVA, Rio de Janeiro, Brazil, 2Pfizer, Inc., São Paulo, Brazil
objeCtives: To compare costs of two delivery systems (pen vs. vials/syringes) 
of recombinant human growth hormone (rGH) in Brazilian GH deficient 
patients. Methods: A budgetary impact model was developed to calculate total 
costs based on product waste (difference between prescribed dose and actual deliv-
ered dose, based on dosing increments for pens [Pfizer Gocquick 16UI and 36UI – P16 
and P36, respectively] and a fixed-percent waste described in the literature for vials 
[Hormotrop 4UI and 12UI – V4 and V12, respectively]) and drug cost. Annual acquisi-
tion costs were calculated based upon total milligrams delivered, for pediatric and 
adult patients. Dose was 0,03mg/kg/day for children and 0,15mg/day for adults. It 
was considered both public and private payer perspectives. Results: For children, 
calculated waste was 2.56% and 7.69% for P16 and P36, respectively; for adults, it was 
0% for both versions. Waste for vials was fixed in 23% for all scenarios. From the pub-
lic payer perspective, total cost per treatment-year for children was BRL26,256.96, 
BRL25,396.38, BRL33,702.73 and BRL32,683.92 for P16, P36, V4 and V12, respectively 
and waste cost was BRL2,019.77, BRL1,953.57, BRL7,751,63 and BRL7,517.30; for 
adults, total cost per treatment-year was BRL3,750.99, BRL3,628.05, BRL5,185,04 
and BRL5,028.30 for P16, P36, V4 and V12, respectively and waste cost was BRL0.00, 
BRL0.00, BRL1,192.56 and BRL1,156,51. From the private payer perspective, total cost 
per treatment-year was, respectively, BRL32,027.03, BRL32,526.11, BRL43,164.19 and 
BRL41,858.67 for P16, P36, V4 and V12, and waste cost was BRL2,586.80, BRL2,502.01, 
BRL9,927.76 and BRL9,627.49 in children; for adults, total cost per treatment-
year was BRL4,804.05, BRL4,646.59, BRL6,640.64 and BRL6,439.79 for P16, P36, 
V4 and V12, respectively and waste cost was BRL0.00, BRL0.00, BRL1,527.35 and 
BRL1,481.15. ConClusions: For pediatric and adult patients, rGH administration 
through pens was less costly, and had less waste than vials/syringes, from both 
public and private perspectives. P36 use was the best option in this analysis.
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healTh care resource uTilizaTion anD cosTs associaTeD wiTh 
various sTages of chronic kiDney Disease among TyPe 2 DiaBeTes 
melliTus PaTienTs
Chuang C.C.1, Lee E.2, Yang E.1, Tawah A.1, Ghosh S.2, Chen S.Y.1
1Evidera, Lexington, MA, USA, 2Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
objeCtives: Uncontrolled type 2 diabetes mellitus (T2DM) increases the risk of 
chronic kidney disease (CKD). This study examined the health care resource utili-
zation (HRU) and costs among T2DM patients with varying degrees of CKD using 
electronic health records. Methods: This retrospective study was conducted using 
electronic health records from US integrated delivery networks from 2008 to 2012. 
Adult T2DM patients (first T2DM diagnosis denotes index date) with continuous 
medical activity during the 6-month pre- and 12-month post-index period and lab 
values for CKD classification were selected. CKD stages were assessed using the 
estimated glomerular filtration rate and urine albumin to creatinine ratio. HRU/costs 
by CKD stage (Stages 1, 2, 3A, 3B, and 4) were captured from the 12-month follow-up 
data and compared to T2DM patients without CKD (no CKD). Unit cost approach was 
applied to derive medical encounter costs. Multivariate regression analyses were 
objeCtives: Patients who do not incorporate diet modifications in their therapy 
regimen may create an undesirable escalation in blood glucose level leading to 
hyperglycemia and chronic complications. The objective of this study is to investi-
gate the prevalence of diabetic patients who incorporate diet modification in their 
therapy, and its association with health care utilization and expenditures for the 
U.S. civilian noninstitutionalized population. Methods: Our study was conducted 
with a quasi-experimental design approach. Subjects included were patients who 
reported being diagnosed with diabetes and reported the treatment of diabetes 
with diet modification from the 2011 Medical Expenditure Panel Survey. A series of 
weighted inferential statistics were used to test the effect of diet modification on 
the variables associated with health care use and expenditures. All analyses were 
accomplished by taking into consideration MEPS sample adjustments using SAS 
9.3. Results: There were an estimated 21.8 million who have been diagnosed with 
diabetes in the US in 2011, of which, 4.6 million (21%) did not include diet modifica-
tion in their therapy. For total health care expenditures, those who did not include 
diet modification had more expenditure (M = $11,230, SE = 811.84) comparing with 
those who included diet modifications (M = $10,638, SE = 487.25), t (172) = 25.26, 
p< .0001. Moreover, total inpatient expenditure for those who did not include diet 
modification (M = $3,003, SE = 497.3) and patients who included diet modification 
(M = $2545.66, SE = 251.45), revealed a significant difference between the groups; t 
(172) = 12.33, p< .0001. ConClusions: The study findings indicated that diabetic 
patients with diet modification had significant lower utilization and expenditures. 
Regulating diet is extremely important for people who have diabetes. It can be very 
effective in preventing or postponing the progression of diabetes, and subsequently 
managing the cost and utilization associated with it.
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TreaTmenT of Brazilian chilDren wiTh growTh hormone Deficiency 
anD Turner synDrome: imPlicaTions of a DaTa-Driven aPProach To 
guiDe Decisions
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objeCtives: To determine cost savings related to growth hormone (GH) treatment 
and impact on height outcome when a data-driven approach is used, compared to 
conventional treatment approach based on experience, in pre-pubertal patients 
with growth hormone deficiency (GHD) and Turner syndrome (TS). Methods: A 
model had been developed previously to study height outcome and total GH cost 
in the presence or absence of data-driven treatment decisions. The proportion of 
patients for whom height outcome could be improved or GH use could be reduced 
(i.e. for low compliance, or high or low responders) was estimated using a cohort 
from the Pfizer International Growth Database (KIGS). This model was adapted to 
Brazilian patients, for both private and public perspectives, resulting in 4 scenarios: 
(1) Genotropin 16UI private, (2) Genotropin 36UI private, (3) Genotropin 16UI public 
and (4) Genotropin 36UI public. Eligible patients were calculated by applying local 
prevalence rates to infant population (n= 13,686 GHD and 15,641 TS). The analysis 
used a 4-year time horizon. Effects were defined as height outcome after 4 years 
and total treatment cost. Results: The analysis estimated that the data-driven 
approach could reduce total cost of GH therapy by 7.1% over 4 years for the treat-
ment of Brazilian patients with GHD and by 6.7% for patients with TS, representing 
a reduction of 7.0% for all subjects. Total costs for all scenarios, when the conven-
tional approach is used were: (1) BRL3,572,931,540.80, (2) BRL3,455,666,095.35, (3) 
BRL2,789,533,217.78 and (4) BRL2,698,326,760.21; with the data-driven approach, total 
costs were: (1) BRL3,327,729,748.47, (2) BRL3,218,511,951.60, (3) BRL2,598,094,188.81 
and (4) BRL2,513,147,013.46. Despite the reduction in treatment costs, the average 
height remained unaffected. ConClusions: In Brazil, the data-driven approach 
could be a useful tool to guide treatment decisions for children with GHD and TS. 
Total costs of GH treatment could be reduced, without having an impact on growth 
outcomes.
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comParison of The DouBly roBusT esTimaTion meThoD To The 
ProPensiTy score meThoD in a DiaBeTes-relaTeD comParaTive healTh 
economics sTuDy
Sun P.1, Lian J.2
1Kailo Research Group, Indianapolis, IN, USA, 2Novo Nordisk Inc., Princeton, NJ, USA
objeCtives: To compare the doubly robust estimation and propensity score meth-
ods in a diabetes-related comparative health economics study. Methods: We used 
large US claims databases that covered 115 million patients between 2000 and 2011. 
Patients with type 2 diabetes with continuous health insurance were selected into 
the intensification cohort or non-intensification cohort depending on whether they 
intensified basal insulin with insulin aspart or remained on treatment with basal 
insulin without bolus insulin. The study measured the patients’ demographic and 
clinical characteristics, as well as their health care utilization and medical costs in 
a 6-month pre-baseline period and a 12-month post-baseline period. Doubly robust 
estimation and propensity score methods were used to examine the impact of inten-
sification on direct medical costs per patient per month (PPPM). Results: The study 
included 26,016 qualified patients with 2,860 in the intensification cohort and 23,156 
in the non-intensification cohort. Baseline characteristics were similar between 
the two cohorts (mean age= 58 years, percentage male= 52%). Both cohorts also had 
similar prevalence rates of diabetes-related conditions, and similar utilization and 
medical costs in the pre-baseline period. The propensity score method indicated 
that the intensification cohort spent $297.4 PPPM less in the post-baseline period 
than the non-intensification cohort (p< 0.05), while the doubly robust estimation 
method estimated a $399.0 PPPM cost reduction due to treatment intensification 
(p< 0.05). The doubly robust estimation method was able to control all confounding 
factors also controlled by the propensity score method, as well as additional con-
founding factors not controlled by the propensity score method. ConClusions: 
Although both the propensity score and doubly robust estimation methods revealed 
cost savings due to treatment intensification with insulin aspart ($297.4 vs. $399.0 
